Development of a New Mouse Model for Lupus Mesenteric Vasculitis and Investigation of Its Aggravation Mechanisms
-
By
-
Maki Fujishiro
-
Kunihiro Hayakawa
-
Yuko Kataoka
-
Marina Shinoura
-
Hiroyuki Tomita
-
Yuna Saito
-
Takuya Nishi
-
Keigo Ikeda
-
Kenji Takamori
-
Iwao Sekigawa
-
Shinji Morimoto
-
September 9, 2026
Clinical Scorecard: Development of a New Mouse Model for Lupus Mesenteric Vasculitis and Investigation of Its Aggravation Mechanisms
At a Glance
| Category | Detail |
|---|
| Condition | Lupus Mesenteric Vasculitis (LMV) |
| Key Mechanisms | Toll-like receptor (TLR) 7/8 agonism and microbiota alterations |
| Target Population | Female NZBWF1 (BWF1) mice aged 8 weeks |
| Care Setting | Animal research facility |
Key Highlights
- R848 administration induced intestinal vasculitis and accelerated SLE pathology in BWF1 mice.
- The model exhibited microbiota alterations and increased fecal propionic acid concentrations.
- Broad-spectrum antibiotics tended to suppress LMV pathology during early induction.
- Propionate administration appeared to attenuate intestinal vasculitis in affected mice.
- The model allows for detailed investigation of LMV pathophysiology.
Guideline-Based Recommendations
Diagnosis
- Diagnosis involves blood testing, imaging, and pathological examination.
Management
- Steroids and immunosuppressants are effective treatments for LMV.
Monitoring & Follow-up
- Monitoring for adverse effects associated with prolonged steroid and immunosuppressant use is recommended.
Risks
- Prolonged use of steroids and immunosuppressants may lead to adverse effects.
Patient & Prescribing Data
BWF1 mice as a model for SLE-related LMV
R848 as a TLR7/8 agonist induces LMV pathology.
Clinical Best Practices
- Utilize an integrated evaluation of imaging findings for diagnosis.
- Consider microbiota involvement in LMV pathogenesis.
Related Resources & Content
